Research Papers:
Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2835 views | HTML 2432 views | ?
Abstract
Yu-Tang Tung1,*, Pin-Wu Huang1,*, Yu-Ching Chou1, Cheng-Wei Lai1, Hsiu-Po Wang1, Heng-Chien Ho2, Chih-Ching Yen1,3, Chih-Yen Tu1,3, Tung-Chou Tsai1, Dah-Cherng Yeh4, Jiun-Long Wang1,5, Kowit-Yu Chong6,7, Chuan-Mu Chen1,8
1Department of Life Sciences, and Agricultural Biotechnology Center, National Chung Hsing University, Taichung 402, Taiwan
2Department of Medicine, China Medical University Hospital, Taichung 404, Taiwan
3Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
4Department of General Surgery and Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan
5Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan
6Department of Medical Biotechnology and Laboratory Sciences, College of Medicine, Chang Gung University, Tao-Yuan 333, Taiwan
7Molecular Medicine Research Center, College of Medicine, Chang Gung University, Tao-Yuan 333, Taiwan
8Rong-Hsing Translational Medicine Center and iEGG Center, National Chung Hsing University, Taichung 402, Taiwan
*These authors have contributed equally to this work
Correspondence to:
Chuan-Mu Chen, e-mail: [email protected]
Keywords: VEGF, transgenic mice, pulmonary tumorigenesis, magnetic resonance imaging (MRI), miRNA therapy
Received: November 03, 2014 Accepted: April 10, 2015 Published: April 22, 2015
ABSTRACT
Many studies have shown that vascular endothelial growth factor (VEGF), especially the human VEGF-A165 (hVEGF-A165) isoform, is a key proangiogenic factor that is overexpressed in lung cancer. We generated transgenic mice that overexpresses hVEGF-A165 in lung-specific Clara cells to investigate the development of pulmonary adenocarcinoma. In this study, three transgenic mouse strains were produced by pronuclear microinjection, and Southern blot analysis indicated similar patterns of the foreign gene within the genomes of the transgenic founder mice and their offspring. Accordingly, hVegf-A165 mRNA was expressed specifically in the lung tissue of the transgenic mice. Histopathological examination of the lung tissues of the transgenic mice showed that hVEGF-A165 overexpression induced bronchial inflammation, fibrosis, cysts, and adenoma. Pathological section and magnetic resonance imaging (MRI) analyses demonstrated a positive correlation between the development of pulmonary cancer and hVEGF expression levels, which were determined by immunohistochemistry, qRT-PCR, and western blot analyses. Gene expression profiling by cDNA microarray revealed a set of up-regulated genes (hvegf-A165, cyclin b1, cdc2, egfr, mmp9, nrp-1, and kdr) in VEGF tumors compared with wild-type lung tissues. In addition, overexpressing hVEGF-A165 in Clara cells increases CD105, fibrogenic genes (collagen α1, α-SMA, TGF-β1, and TIMP1), and inflammatory cytokines (IL-1, IL-6, and TNF-α) in the lungs of hVEGF-A165-overexpressing transgenic mice as compared to wild-type mice. We further demonstrated that the intranasal administration of microRNA-16 (miR-16) inhibited lung tumor growth by suppressing VEGF expression via the intrinsic and extrinsic apoptotic pathways. In conclusion, hVEGF-A165 transgenic mice exhibited complex alterations in gene expression and tumorigenesis and may be a relevant model for studying VEGF-targeted therapies in lung adenocarcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3390